News Breaks |
|
|
| December 5, 2012 |
| 06:25 EDT |  | LLY | Eli Lilly, Strides Arcolab enter strategic partnership agreement
Eli Lilly and Company and Strides Arcolab Limited announced a collaboration to expand delivery of cancer medicines in the emerging markets. As a part of this arrangement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, based in Bangalore, India. Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these medications in multiple geographies across the emerging markets. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future. |
|
|
News For LLY From The Last 14 Days Check below for free stories on LLY the last two weeks. |
|
|
| May 16, 2013 |
| 08:55 EDT |  | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
 Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
| May 9, 2013 |
| 11:01 EDT | | LLY | Sears Holdings names Jeff Balagna Chief Information Officer
Subscribe for More Information |
|
| May 6, 2013 |
| 18:42 EDT | | LLY | Eli Lilly and Boehringer announce results from Phase 3 study of linagliptin
Subscribe for More Information |
|
| 16:40 EDT | | LLY | Eli Lilly announces CEO Dr. John Lechleiter to undergo surgery
Subscribe for More Information |
|
|
|
|
|
